Gefitinib Myths: — What the Evidence Actually Shows

Gefitinib is a cheap drug because it does not work as well as newer ones

Gefitinib is a first-generation EGFR tyrosine kinase inhibitor with a well-established evidence base. NCCN and ESMO both list it as a first-line option for EGFR-mutated non-small cell lung cancer. Its price has fallen as the patent expired and generics became available — that is a market factor, not a measure of how well it works. Whether a first- or second-generation agent is right for you depends on clinical factors your oncologist will explain. People believe this myth because in most areas of life, price and quality move together. In medicines, they often do not.

Gefitinib causes hair loss and severe nausea like chemotherapy

Gefitinib works differently from chemotherapy and has a different side effect profile. The most common effects are skin rash, dry skin, mouth sores and loose motions. Significant hair loss and severe vomiting are not typical. This matters practically — many people on gefitinib maintain daily routines in a way that intensive chemotherapy often does not allow. The confusion comes from lumping all cancer treatments together, when targeted therapy and chemotherapy act on completely different mechanisms.

If gefitinib stops working, there is nothing left to try

When gefitinib stops working, the standard next step is re-testing — a new tissue biopsy or a liquid biopsy — to identify what changed in the tumour. A resistance mutation called T790M is found in a proportion of cases and can be targeted with a later-line agent. Other resistance mechanisms point to other treatment options. 'Gefitinib has stopped working' is the beginning of a clinical conversation about what changed, not a signal that treatment has ended. This myth persists because resistance sounds like failure. In oncology, it is a data point.

Gefitinib is only prescribed when the doctor has given up on you

Gefitinib is a first-line treatment for EGFR-mutated lung cancer — used at the start, not after everything else has failed. Being prescribed it means the EGFR mutation test on your tumour tissue came back positive and that targeted therapy is the appropriate first step. A doctor prescribing gefitinib is following the evidence, not stepping back from it. This myth likely comes from older practice, before routine EGFR testing, when the drug was used more broadly and in later lines.

You must avoid all spicy food, herbal medicines and supplements on gefitinib

Specific interactions are worth knowing about — certain antacids and proton pump inhibitors can reduce how much gefitinib your body absorbs, and smoking affects the drug's activity. But a blanket ban on food or all supplements is not part of clinical guidance. What matters most is telling your oncology team everything you are taking, including Ayurvedic preparations and over-the-counter remedies, so they can identify anything that might genuinely interfere. The conversation is practical, not a judgement on traditional medicine.